Seastar Medical Holding CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
SeaStar Medical Holding Corporation's latest 10-K filing reveals increased revenue from its pediatric SCD therapy but highlights substantial doubt about its ability to continue as a going concern due to ongoing losses and capital needs.
NASDAQ
SeaStar Medical Holding Corporation files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information, correct typographical errors, and file new certifications.
NASDAQ
SeaStar Medical's 10-K filing details its 2024 financial results, commercial progress with its FDA-approved pediatric device, and ongoing clinical trials for its adult AKI therapy.
NASDAQ
10-K/A: SeaStar Medical Holding Corporation Details Capital Structure and Warrant Terms in Amended Filing
SeaStar Medical Holding Corporation provides a detailed description of its common stock, warrants, and anti-takeover provisions in an amended 10-K filing.
NASDAQ
SeaStar Medical has filed an amendment to its annual report to correct typographical errors, include previously omitted information, and update share information.
NASDAQ
SeaStar Medical's 2023 annual report highlights FDA approval for its pediatric device, ongoing clinical trials for adults, and significant financial losses.